Edwards Lifesciences (EW) Liabilities and Shareholders Equity (2016 - 2026)
Edwards Lifesciences has reported Liabilities and Shareholders Equity over the past 17 years, most recently at $13.7 billion for Q4 2025.
- For Q4 2025, Liabilities and Shareholders Equity rose 4.92% year-over-year to $13.7 billion; the TTM value through Dec 2025 reached $53.5 billion, up 16.61%, while the annual FY2025 figure was $13.7 billion, 4.92% up from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 was $13.7 billion at Edwards Lifesciences, up from $13.3 billion in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $13.7 billion in Q4 2025 and troughed at $7.2 billion in Q1 2021.
- A 5-year average of $10.1 billion and a median of $9.2 billion in 2023 define the central range for Liabilities and Shareholders Equity.
- Biggest five-year swings in Liabilities and Shareholders Equity: dropped 2.47% in 2022 and later soared 39.43% in 2024.
- Year by year, Liabilities and Shareholders Equity stood at $8.5 billion in 2021, then dropped by 2.47% to $8.3 billion in 2022, then rose by 12.91% to $9.4 billion in 2023, then soared by 39.43% to $13.1 billion in 2024, then rose by 4.92% to $13.7 billion in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for EW at $13.7 billion in Q4 2025, $13.3 billion in Q3 2025, and $13.5 billion in Q2 2025.